| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/27/2011 | US20110020311 Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy |
| 01/27/2011 | US20110020306 Probiotic, Lactic Acid-Producing Bacteria and Uses Thereof |
| 01/27/2011 | US20110020305 Probiotic, Lactic Acid-Producing Bacteria and Uses Thereof |
| 01/27/2011 | US20110020300 Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes |
| 01/27/2011 | US20110020290 Bacteriophage-containing therapeutic agents |
| 01/27/2011 | US20110020283 Probiotic, gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in humans |
| 01/27/2011 | US20110020279 Rabies cure |
| 01/27/2011 | US20110020278 Inhibitors of flaviviridae viruses |
| 01/27/2011 | US20110020277 Dioxolane and Dioxolanone Fused Indolobenzadiazepine HCV NS5B Inhibitors |
| 01/27/2011 | US20110020276 Pyrrolidine Fused Indolobenzadiazepine HCV NS5B Inhibitors |
| 01/27/2011 | US20110020275 Compounds for the Treatment of Hepatitis C |
| 01/27/2011 | US20110020274 Mobilization of hematopoietic stem cells |
| 01/27/2011 | US20110020272 Combination therapy for treating hepatitis viral infection |
| 01/27/2011 | US20110020270 Treatment and prophylaxis |
| 01/27/2011 | US20110020267 Tweak receptor |
| 01/27/2011 | US20110020265 Use of oligomers of lactic acid in the treatment of gynaecological disorders |
| 01/27/2011 | US20110020264 Method and Composition for the Treatment of Scars |
| 01/27/2011 | US20110020244 Pharmaceutical compositions |
| 01/27/2011 | US20110020243 Methods and compositions for imaging cancer cells |
| 01/27/2011 | US20110020234 Rna interference mediating small rna molecules |
| 01/27/2011 | US20110020232 Cancer treatment with gama-secretase inhibitors |
| 01/27/2011 | US20110020231 Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists |
| 01/27/2011 | US20110020229 Multi-Component Biological Transport Systems |
| 01/27/2011 | US20110020228 Targeted cellular selectivity of surface active molecules |
| 01/27/2011 | US20110020227 Polysaccharide-containing block copolmer particles and uses thereof |
| 01/27/2011 | US20110020226 Particle structures comprising sterols and saponins |
| 01/27/2011 | US20110020220 Humanized antibodies against the beta-amyloid peptide |
| 01/27/2011 | US20110020217 Treatment of melanoma |
| 01/27/2011 | US20110020216 Scaffolds for cell collection or elimination |
| 01/27/2011 | US20110018866 Structure of the farnesoid x receptor ligand binding domain and methods of use therefor |
| 01/27/2011 | DE102009034525A1 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten 17-hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl-derivatives, processes for their preparation and their use for the treatment of diseases |
| 01/27/2011 | DE102009034368A1 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten 17-hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenphenyl derivatives, processes for their preparation and their use for the treatment of diseases |
| 01/27/2011 | DE102009034367A1 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten 17-hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-benzylidene derivatives, processes for their preparation and their use for the treatment of diseases |
| 01/27/2011 | DE102009034366A1 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten 17-hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-methylenoxyalkylenaryl derivatives, processes for their preparation and their use for the treatment of diseases |
| 01/27/2011 | DE102009034362A1 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten 17-hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl-derivatives, processes for their preparation and their use for the treatment of diseases |
| 01/27/2011 | DE102009034131A1 Composition, useful e.g. as volume substitute, and for prophylaxis and therapy of reperfusion syndrome and hypovolemia, comprises an aqueous composition of inosine and a hydrocolloid including hydroxyethyl starch, gelatin and/or albumin |
| 01/27/2011 | DE102009034130A1 Aqueous pharmaceutical preparation, useful for the prevention of renal failure, comprises an aminoglycoside antibiotic, gelatin and/or its derivatives and/or a gelatin-like protein or polypeptide and sodium chloride |
| 01/27/2011 | DE102009027938A1 Oral dosage form, useful to administer active agent to human/animal and treat organism or its (patho)physiological conditions, comprises a base body with an opening, where the body contains an active agent formulation and blowing agent |
| 01/27/2011 | CA2804215A1 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| 01/27/2011 | CA2775443A1 Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) |
| 01/27/2011 | CA2769474A1 Acyl guanidine derivatives modulating the hedgehog protein signaling pathway |
| 01/27/2011 | CA2769133A1 Cell protection in dialysis patients by administration of a creatine compound |
| 01/27/2011 | CA2768980A1 Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders |
| 01/27/2011 | CA2768963A1 Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| 01/27/2011 | CA2768947A1 Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| 01/27/2011 | CA2768881A1 Fused aminodihydropyrimidone derivatives |
| 01/27/2011 | CA2768851A1 Inhibitors of mtor kinase as anti-viral agents |
| 01/27/2011 | CA2768843A1 Treatment of liver disorders with pi3k inhibitors |
| 01/27/2011 | CA2768832A1 Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators |
| 01/27/2011 | CA2768767A1 Crude caffeine complex, improved food products using the crude caffeine complex, and methods of use thereof |
| 01/27/2011 | CA2768710A1 Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies |
| 01/27/2011 | CA2768668A1 Galantamine amino acid and peptide prodrugs and uses thereof |
| 01/27/2011 | CA2768656A1 Ferric citrate dosage forms |
| 01/27/2011 | CA2768631A1 Combination therapies with ck2 modulators |
| 01/27/2011 | CA2768577A1 Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| 01/27/2011 | CA2768541A1 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases |
| 01/27/2011 | CA2768532A1 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl derivatives, methods for the production thereof and use thereof for treating diseases |
| 01/27/2011 | CA2768471A1 Methods of attenuating the loss of functional status |
| 01/27/2011 | CA2768466A1 Hdac inhibitors and therapeutic methods using the same |
| 01/27/2011 | CA2768461A1 Vitamin c and vitamin k, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant |
| 01/27/2011 | CA2768457A1 Pharmaceutical compositions |
| 01/27/2011 | CA2768453A1 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases |
| 01/27/2011 | CA2768448A1 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylene oxyalkylene aryl derivatives, methods for the production thereof and the use thereof for treating diseases |
| 01/27/2011 | CA2768433A1 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases |
| 01/27/2011 | CA2768407A1 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and use thereof for treating diseases |
| 01/27/2011 | CA2768373A1 Heteroaryl benzamides, compositions and methods of use |
| 01/27/2011 | CA2768333A1 1h-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis |
| 01/27/2011 | CA2768088A1 Method of making cefquinome particles |
| 01/27/2011 | CA2768024A1 A stable pharmaceutical omeprazole formulation for oral administration |
| 01/27/2011 | CA2767967A1 Multi-layered gradient vaginal ring |
| 01/27/2011 | CA2767888A1 Tamper-resistant dosage form for oxidation-sensitive opioids |
| 01/27/2011 | CA2767772A1 Potent small molecule inhibitors of autophagy, and methods of use thereof |
| 01/27/2011 | CA2767463A1 Benzoquinolizinium salt derivatives as anticancer agents |
| 01/27/2011 | CA2767088A1 Inhibitors of flaviviridae viruses |
| 01/27/2011 | CA2766522A1 Pyridone glucokinase activators |
| 01/27/2011 | CA2766172A1 Oxidation-stabilized tamper-resistant dosage form |
| 01/27/2011 | CA2765971A1 Hot-melt extruded controlled release dosage form |
| 01/27/2011 | CA2761600A1 Fentanyl-containing adhesive preparation for external use |
| 01/26/2011 | EP2278012A2 Avirulent, immunogenic flavivirus chimeras |
| 01/26/2011 | EP2278011A2 Neisseria meningitidis antigens |
| 01/26/2011 | EP2278005A2 Fuctional and hyperfunctional sirna |
| 01/26/2011 | EP2278004A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 01/26/2011 | EP2277991A1 Method and quantification assay for determining c-kit/SCF/pAKT status |
| 01/26/2011 | EP2277919A1 Treatment with anti-ERBB2 antibodies |
| 01/26/2011 | EP2277898A2 Rapamycin analogues |
| 01/26/2011 | EP2277885A1 Glycosylated indolecarbazoles, method for obtaining same and uses thereof |
| 01/26/2011 | EP2277884A1 Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof |
| 01/26/2011 | EP2277882A1 Pipéridinic compounds, process for their préparation and pharmaceutical compositions containing them |
| 01/26/2011 | EP2277881A1 Heterocyclic compound having inhibitory activity on p13k |
| 01/26/2011 | EP2277880A1 Macrolides with VEGF transcription suppression activity |
| 01/26/2011 | EP2277878A1 Process for production of ethynylthymidine compound using 5-methyluridine as starting raw material |
| 01/26/2011 | EP2277877A1 Quinazoline derivatives as kinase inhibitors |
| 01/26/2011 | EP2277876A1 Substituted pyrimidines for the treatment of cancer |
| 01/26/2011 | EP2277874A1 Activator for peroxisome proliferator-activated receptor |
| 01/26/2011 | EP2277873A1 Intermediate compound for the preparation of halichondrin analogs |
| 01/26/2011 | EP2277867A2 Compounds, pharmaceutical compositions thereof and their use in treating cancer |
| 01/26/2011 | EP2277865A1 Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors |
| 01/26/2011 | EP2277863A1 Piperidine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/26/2011 | EP2277862A2 5-hydroxy-4-aminomethyl-1-cyclohexane or (cycloheptyl)--3-alkoxycarbonyl indole derivatives, pharmaceutically acceptable antiviral salts thereof and a method for the production thereof |
| 01/26/2011 | EP2277861A1 Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same |